Accuracy of PET-CT in Predicting Survival in Patients with Esophageal Cancer
- 284 Downloads
Positron emission tomography (PET) is an integral part of tumor staging for patients with esophageal cancer. Recent studies suggest a role for PET scan in predicting survival in these patients, but this relationship is unclear in the setting of neoadjuvant therapy. We examined pretreatment maximum standard uptake value (SUVmax) of the primary tumor in patients treated with and without neoadjuvant therapy.
All patients undergoing esophagectomy with a preoperative PET scan over a nine-year period (2001–2010) were identified from a prospectively maintained database. Positron emission tomography data were obtained from computers housing the original PET scans. Overall survival was correlated with SUVmax of the primary tumor.
A total of 191 patients were identified, and 103 patients met inclusion criteria. Eighty-two had an adenocarcinoma (80%), and 21 (20%) had a squamous cell carcinoma. Fifty-seven (55%) patients received neoadjuvant therapy. In the surgery alone group, a SUVmax of > 5.0 in the primary tumor was associated with poor prognosis [Hazard Ratio (HR) 0.32; p = 0.007], but this factor did not retain its significance on multivariate analysis (HR 0.65; p = 0.43). Pretreatment SUVmax in patients who underwent neoadjuvant therapy was not significant in predicting overall survival (p = 0.10).
This study does not support the use of SUVmax on pretreatment PET scans as a prognostic tool for patients with esophageal cancer, especially in those who have received neoadjuvant therapy. Lymph node status is a more accurate predictor of outcome, and efforts to improve pretreatment staging should focus on this factor.
- 1.National Comprehensive Cancer network, Inc (2010) NCCN practice guidelines in oncology. Esophageal cancer. Version 1.2010. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [accessed November 8, 2010]
- 2.Skehan SJ, Brown AL, Thompson M et al (2003) Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 20:713–723Google Scholar
- 11.Medical Services Advisory Committee (2008) Positron emission tomography for oesophageal and gastric cancer. Assessment report. Available at http://www.msac.gov.au/internet/msac/publishing.nsf/Content/8FD1D98FE64C8A2FCA2575AD0082FD8F/$File/MSAC_35b_i__PET_gastroesophageal_toprint_FINAL%20to%20print_301008.pdf [accessed November 12, 2010]
- 12.Wong R, Walker-Dilks C, Raifu AO (2009) Recommendation report—PET #4. PET imaging in esophageal cancer. Available at: http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=43135 [accessed December 12, 2010]
- 13.Palser T, Cromwell D, van der Meulen et al. (2008) National oesophago-gastric cancer audit: an audit of the care received by people with oesophago-gastric cancer in England and Wales. First Annual Report 2008. Available at http://www.ic.nhs.uk/webfiles/Services/NCASP/Cancer/New%20web%20documents%20(OG)/28010208-NHSIC-OGAuditReport-FV-HR.pdf [accessed December 12, 2010]
- 14.Facey K, Bradbury I, Laking G et al. (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11:iii–iv, xi–267Google Scholar
- 23.Westreenen HL, Plukker JTM, Cobben DCP (2005) Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol Radium Ther Nucl Med 185:436–440Google Scholar
- 36.West CML, Charnley N (2005) The potential of PET to increase understanding of the biological basis of tumor and normal tissue response to radiotherapy. Br J Radiol Suppl 28:50–54Google Scholar
- 42.Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar